Clinical trial
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric…
NCT03000439 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT03000439 |
|---|---|
| Title | A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA |
| Official title | EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthritis Juvenile Idiopathic |
| Intervention type | Drug |
| Interventions | In open-label phase: treatment with tofacitinib, In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio |
| Enrollment | 100 |
| Start date | May 10, 2018 |
| Primary completion | Mar 27, 2024 |
| Completion | Mar 27, 2024 |
| First posted | Dec 22, 2016 |
| Last update posted | Jun 3, 2025 |
| Countries | Argentina, Belgium, Brazil, Canada, China, Costa Rica, Germany, Hungary, India, Israel, Italy, Mexico and 7 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: